CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

Leukemia and Lymphoma

Volumn 51, Issue 9, 2010, Pages 1643-1648

  Rydström, Karin ^a   Linderoth, Johan ^a   Nyman, Heidi ^b   Ehinger, Mats ^a   Joost, Patrick ^a   Bendahl, Pär Ola ^a   Leppä, Sirpa ^b   Jerkeman, Mats ^a  

^a LUND UNIVERSITY   (Sweden)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

CD40; diffuse large B cell lymphoma; Lymphoma; prognostication

Indexed keywords

CD40 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ANTIGEN EXPRESSION; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RATING SCALE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD40; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DNA-BINDING PROTEINS; DOXORUBICIN; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOTHERAPY; INTERFERON REGULATORY FACTORS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE; YOUNG ADULT;

EID: 77956324601     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.492537     Document Type: Article

References (22)

1. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346: 235-242.
2. Shipp MA, Anderson JR, Armitage JO, Bonnadonna G, Brittinger GA. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329: 987-994.
3. Linderoth J, Jerkeman M, Cavallin-Stahl E, Kvaloy S, Torlakovic E. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study. Clin Cancer Res 2003;9:722-728.
4. Linderoth J, Ehinger M, Jerkeman M, et al. CD40 expression identifies a prognostically favourable subgroup of diffuse large B-cell lymphoma. Leuk Lymphoma 2007;48:1774-1779.
5. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282.
6. Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, Banham AH, Enblad G, Leppa S. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas. Eur J Haematol 2009;82:364-372.
7. Altman DG. Practical statistics for medical research. London: Chapman & Hall; 1991. p. 394.
8. Nyman H, Adde M, Karjalainen-Lindsberg ML, et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007;109:4930-4935.
9. Fu K, Weisenburger DD, Choi WW, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008;26:4587-4594.
10. Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 2008;26:2717-2724.
11. Winter JN, Weller EA, Horning SJ, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006;107:4207-4213.
12. de Jong D, Xie W, Rosenwald A, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium). J Clin Pathol 2009;62:128-138.
13. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000;67:2-17.
14. Vestal RE, Wingett D, Freeman G. Expression of CD40 in breast, colon, lung and ovarian tumours. Proc Am Assoc Cancer Res 1997;38:230 (Abstract 1550).
15. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998;393:478-480.
16. Vonderheide RH. Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res 2007;13:1083-1088.
17. French RR, Chan HT, Tutt AL, Glennie MJ. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 1999;5:548-553.
18. Planken EV, Dijkstra NH, Willemze R, Kluin-Nelemans JC. Proliferation of B cell malignancies in all stages of differentiation upon stimulation in the 'CD40 system'. Leukemia 1996;10:488-493.
19. Funakoshi S, Longo DL, Beckwith M, et al. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 1994;83:2787-2794.
20. Szocinski JL, Khaled AR, Hixon J, et al. Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: induction of bax. Blood 2002;100:217-223.
21. Saito M, Gao J, Basso K, et al. A signaling pathway mediating down regulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell 2007;12:280-292.
22. Parekh S, Polo JM, Shaknovich R, et al. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. Blood 2007;110:2067-2074.